GlassScriptPhysician profile
Christian Hernandez
NPI 1659705465
$3,804.66
in general payments reported to CMS, 2019-2025
22 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $299 · 2021: $569 · 2022: $555 · 2023: $952 · 2024: $571 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,667 · Consulting Fee: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.75 |
| Consulting Fee | $180.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,440.27 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $838.72 | 2019-2025 | Dailies Total1, Total30, Dailies |
| Abbvie INC. | $324.22 | 2023-2025 | |
| Coopervision INC. | $151.06 | 2019-2024 | Paragon Crt, Synergeyes Contact Lens |
| Bausch & Lomb Americas INC. | $146.48 | 2022-2025 | Infuse, Miebo, Xiidra |
| Topcon Healthcare, INC. | $135.20 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $107.37 | 2019-2021 | |
| Biotissue Holdings INC. | $102.34 | 2025 | |
| Oyster Point Pharma, INC. | $96.54 | 2023-2024 | Tyrvaya, Ryzumvi |
| Maculogix, INC. | $86.82 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $80.84 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $66.61 | 2019-2021 | |
| Allergan, INC. | $44.42 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $31.65 | 2020-2022 | |
| Dompe US, INC. | $29.60 | 2025 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $28.26 | 2024 | Iyuzeh |
| Harrow Eye, LLC | $26.00 | 2025 | Vevye |
| Amgen INC. | $19.25 | 2024 | Tepezza |
| Shire North American Group INC | $15.62 | 2019 | |
| Visioneering Technologies, INC. | $14.06 | 2019 | |
| Aerie Pharmaceuticals, INC. | $11.33 | 2019 | |
| Abb Con-Cise Optical Group LLC | $8.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.